Tuesday, December 26, 2017
Centinel Spine, LLC (CS) is pleased to announce the acquisition of the worldwide assets of the prodisc® Total Disc Replacement portfolio from DePuy Synthes Products, Inc. The prodisc line of products are total disc replacement (TDR) products with the longest history of use globally. The prodisc® portfolio includes prodisc® C and prodisc® L in the United States and prodisc® VIVO, prodisc® NOVA, prodisc® C, prodisc® L, and prodisc® O, along with DISCOVER™ Cervical outside the United States.
This acquisition complements Centinel Spine's existing spinal implant portfolio of leading technologies for anterior column support of the spine from cervical to lumbar. This includes the company's standalone portfolio of STALIF C®, STALIF C-Ti™, MIDLINE II™, MIDLINE II-Ti™, and STALIF L™, as well as additional products ACTILIF™ Cervical Cage TRANSOM™ Plate, and ALTOS® PCT.
Centinel Spine, the pioneer of the No-Profile®, Integrated Interbody™ has a 30 year history of developing integrated interbody devices into a standard treatment for patients with degenerated disc disease. Centinel Spine will utilize the same clinical, regulatory, and development expertise to broaden acceptance and to increase carrier coverage and surgeon adoption of total discs worldwide.
"This transaction is the next step in the evolution of Centinel Spine executing on its mission to become the worldwide leading company addressing spinal disease through anterior access to the spine with the widest breadth and depth of technology platforms," said John J. Viscogliosi, Centinel Spine Chairman & CEO.
For background in understanding the acquisition, Viscogliosi Brothers, LLC, a lead investor in Centinel Spine, was the founder of Spine Solutions, Inc., the company that led the original IDE study to bring prodisc to the United States.
The company also completed debt and equity financing to close on the transaction and provide working capital. Piper Jaffray & Co. served as the sole placement agent for Centinel Spine.
